Skip to content

Evaluation of the effect of using mobile health technology on reducing cardiovascular risk scores

A randomized clinical trial of the design and implementation and evaluation of the impact of Mobile-Health Technology-Based intervention on primary prevention of cardiovascular risk factors and assessment of its efficacy in reducing cardiovascular risk score

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250503065573N1
Enrollment
300
Registered
2025-09-14
Start date
2025-09-06
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular risk factors. Atherosclerotic heart disease of native coronary artery

Interventions

Intervention 1: Intervention group: Participants in the intervention group will receive Salamat Hamrah, a mobile-health web-based application designed to support cardiovascular risk reduction. This ap

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Having at least one uncontrolled risk factor including: uncontrolled hypertension, uncontrolled dyslipidemia and current cigarette smoking for =12 months and SCORE risk of high (5-9%) or very high (=10%) Having and ability of using smart phone by the participant or one of his/her trustworthy relatives who lives near him/her Willing to control the risk factors using App

Exclusion criteria

Exclusion criteria: History of Coronary artery disease defined as history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, coronary angiography confirming stenosis>50% in at least one of the major epicardial coronary arteries or their main branches Individuals with at require prohibitive morbidity that close face-to-face monitoring End stage chronic disease such as: hepatic and/or renal failure, heart failure Active cancer Mental retardation

Design outcomes

Primary

MeasureTime frame
Reduction of cardiovascular risk score. Timepoint: 3 months after intervention. Method of measurement: Laboratory measurement of blood LDL level, Digital blood pressure monitor or Mercury sphygmomanometer, Self-reported smoking cessation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedeh Hamideh Mortazavi

Tehran University of Medical Sciences

hamideh.mortazavi@gmail.com+98 21 8802 9600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026